Table 4 Comparison of prevalence of transient CHL between the groups of infants with and without risk factors for hearing impairment (n = 337).
| Risk factor | Infants with risk factor | Infants without risk factor | p Value | ||
|---|---|---|---|---|---|
| Total | No with CHL | Total | No with CHL | ||
| Apgar 0–4 at 1 min and/or 0–6 at 5 min* | 42 | 4 | 272 | 5 | <0.01 |
| RDS | 215 | 8 | 122 | 1 | NS |
| BPD (O2 >28 days) | 52 | 4 | 285 | 5 | 0.01 |
| Mechanical ventilation ⩾5 days | 145 | 6 | 192 | 3 | NS |
| Ototoxic drugs ⩾10 days | 154 | 6 | 183 | 3 | NS |
| Bilirubin >13 mg%* | 16 | 0 | 298 | 9 | NS |
| IVH (grades 3–4) | 8 | 0 | 329 | 9 | NS |
| PVL | 21 | 0 | 316 | 9 | NS |
| Neurological symptoms* | 42 | 1 | 272 | 8 | NS |
| In utero infection* | 2 | 0 | 312 | 9 | NS |
| Proven sepsis (early & late) | 60 | 3 | 277 | 6 | NS |
| Familial history of SNHL* | 11 | 0 | 303 | 9 | NS |
*Only 314 infants with known data.
CHL, Conductive hearing loss; RDS, respiratory distress syndrome; BPD, bronchopulmonary dysplasia; IVH, intraventricular haemorrhage; PVL, periventricular leucomalacia; SNHL, sensory‐neural hearing loss.